China Pharma Holdings, Inc. (CPHI) News

China Pharma Holdings, Inc. (CPHI): $0.36

0.03 (+8.87%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add CPHI to Watchlist
Sign Up

Industry: China

Industry

C

Ranked

#23 of 49

in industry

Filter CPHI News Items

CPHI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest CPHI News From Around the Web

Below are the latest news stories about CHINA PHARMA HOLDINGS INC that investors may wish to consider to help them evaluate CPHI as an investment opportunity.

China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China.

Yahoo | November 29, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Pre-market stock movers are a hot topic this morning and we're checking on the biggest ones investors will want to watch on Friday!

William White on InvestorPlace | September 22, 2023

Is China Pharma Holding (CPHI) A Hidden Gem or A Value Trap?

Unraveling the Financial Health of China Pharma Holding

Yahoo | August 23, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the week off right with a look at the biggest pre-market stock movers worth watching on Monday morning!

William White on InvestorPlace | August 21, 2023

China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its wholly-owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd. (hereinafter referred to as "Helpson") has received the "Drug Supplementary Application Approval Notice" for its candesartan tablets by National Medical Products Administration of China (hereinafter referred to as NMPA"), indicating that the Company's candesartan tablets hav

Yahoo | August 9, 2023

China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Monday, March 6, 2023, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T-203.

Yahoo | February 24, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!